Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
This intro covers Wash Sale Rule 61 Day Window Dividend ETF, detailing the 61-day period and its implications for replacements.
18,680 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
AMD posted a blowout Q1 FY2026 with record revenue and booming data-center sales. The company guides stronger-than-ex...
A six-story glass building in Manhattan's Chinatown sits at the center of a courtroom fight over whether it was a cov...
A new study shows Gen Z treats streaming like short-term rentals, churning between services and titles, challenging t...
This guide digs into plains (pagp) 2026 earnings, translating a complex earnings transcript into practical insights f...
A federal court clears a $71 million ETH transfer on Arbitrum to Aave, but North Korea-linked creditors retain legal ...
President Trump pushes to suspend the federal gas tax to lower pump prices, but analysts say higher oil prices and fu...
A dramatic rise in gold shipments from the United States propelled exports to new highs in early 2026, signaling a sh...
QXO unveiled a detailed growth plan after a sweeping, roughly $30B M&A spree, outlining how TopBuild will fit into it...
Micron Technology rides a rapid AI-fueled rally into May, fueling debate among investors about whether to sell or hol...
Upshift launches a new vault platform to deliver instant liquidity for real-world asset redemptions, backed by dedica...
Intuitive Surgical has faced a sharp stock pullback this year. This article breaks down the factors behind the move, ...